A new study published in JAMA Internal Medicine reveals that more than $9.8 billion was spent on treating five major health care-associated infections (HAIs), with surgical site infections accounting for the highest costs.
HAIs are associated with high costs and better evaluation of the cost of these infections could help providers and payers justify investing in prevention, according to background information in the study by Eyal Zimlichman, M.D., M.Sc., of Brigham and Women's Hospital and the Harvard Medical School, Boston, and colleagues.
Researchers reviewed published medical literature for the years 1986 through April 2013. For HAI incidence estimates, researchers used the National Healthcare Safety Network of the Centers for Disease Control and Prevention (CDC).
"As one of the most common sources of preventable harm, health care-associated infections (HAIs) represent a major threat to patient safety," the authors note. "The purpose of this study was to generate estimates of the costs associated with the most significant and targetable HAIs."
According to the results, on a per-case basis, the central line-associated bloodstream infections were found to be the most costly HAIs at $45,814, followed by ventilator-associated pneumonia at $40,144, surgical site infections at $20,785, Clostridium difficile infection at $11,285 and catheter-associated urinary tract infections at $896.
"While quality improvement initiatives have decreased HAI incidence and costs, much more remains to be done. As hospitals realize savings from prevention of these complications under payment reforms, they may be more likely to invest in such strategies," the study concludes.
(JAMA Intern Med. Published online September 2, 2013. doi:10.1001/jamainternmed.2013.9763.)
Editor's Note: This study was sponsored by the Texas Medical Institute of Technology, Austin, as part of a donation promoting research on patient safety. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.